Vir Singh Negi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vir Singh Negi has a total of 210 co-authors. Here are the top co-authors by number of shared publications:
- Chengappa Kavadichanda
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research , Puducherry
28 shared publications - Durga Prasanna Misra
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India
19 shared publications - Molly Mary Thabah
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
11 shared publications - Aishwarya Gopal
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research , Puducherry
9 shared publications - Aman Sharma
Division of Clinical Immunology and Rheumatology, Department of Internal Medicine Postgraduate Institute of Medical Education and Research Chandigarh India
9 shared publications - Vikas Agarwal
Department of Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences , Lucknow
9 shared publications
Latest Publications
- 30 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Rituximab for the treatment of calcinosis in dermatomyositis: a case series and review of the literature
Objectives: Dystrophic calcinosis, a frequent complication of DM and JDM is poorly responsive to treatment. We analysed the outcomes of calcinosis in patients with idiopathic inflammatory myositis (IIM) and calcinosis treated with rituximab. Methods: IIM patients with calcinosis who received at least one cycle of rituximab (750 mg/m2 in adults and 575 mg/m2 in children on days 1 and 14) were included. Baseline data included MMT8, patient global assessment, physician global assessment, myositis-specific and myositis-associated antibodies, duration, location and morphological pattern on plain radiographs of calcinosis. Improvement was defined as any reduction of calcinosis on plain radiographs. Results: Of 224 IIM patients, 18 had calcinosis of whom 10 received rituximab (six JDM and four adult patients). Five of 10 patients were anti-NXP2, other MSAs were anti-MDA5, anti-PL7 and anti-Mi2. Seven of 10 patients had calcinosis at presentation; three developed subsequently. Predominant morphologies (radiographically) were nodular and sheet-like; two had mixed patterns. Eight of 10 patients also had active myositis (MITAX A or B) at rituximab initiation—of these, all showed either improvement or stabilization. Of the two with inactive disease treated solely for calcinosis, one stabilized; the other worsened. The one patient who worsened had diffuse distribution and mixed morphology of calcinosis. Conclusion: In this small series, rituximab initiation during active myositis was associated with improvement or stabilization of calcinosis; however, given the limited sample size, this observation should be interpreted cautiously and requires prospective validation.
- 30 October 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Rituximab for the treatment of calcinosis in dermatomyositis: a case series and review of the literature
Objectives: Dystrophic calcinosis, a frequent complication of DM and JDM is poorly responsive to treatment. We analysed the outcomes of calcinosis in patients with idiopathic inflammatory myositis (IIM) and calcinosis treated with rituximab. Methods: IIM patients with calcinosis who received at least one cycle of rituximab (750 mg/m2 in adults and 575 mg/m2 in children on days 1 and 14) were included. Baseline data included MMT8, patient global assessment, physician global assessment, myositis-specific and myositis-associated antibodies, duration, location and morphological pattern on plain radiographs of calcinosis. Improvement was defined as any reduction of calcinosis on plain radiographs. Results: Of 224 IIM patients, 18 had calcinosis of whom 10 received rituximab (six JDM and four adult patients). Five of 10 patients were anti-NXP2, other MSAs were anti-MDA5, anti-PL7 and anti-Mi2. Seven of 10 patients had calcinosis at presentation; three developed subsequently. Predominant morphologies (radiographically) were nodular and sheet-like; two had mixed patterns. Eight of 10 patients also had active myositis (MITAX A or B) at rituximab initiation—of these, all showed either improvement or stabilization. Of the two with inactive disease treated solely for calcinosis, one stabilized; the other worsened. The one patient who worsened had diffuse distribution and mixed morphology of calcinosis. Conclusion: In this small series, rituximab initiation during active myositis was associated with improvement or stabilization of calcinosis; however, given the limited sample size, this observation should be interpreted cautiously and requires prospective validation.
- 1 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Antiphospholipid antibody trajectories and clinical correlates in an inception cohort of systemic lupus erythematosus
Objective: To evaluate longitudinal antiphospholipid antibody (aPL) patterns in newly diagnosed systemic lupus erythematosus (SLE) and their association with vascular events, disease activity and organ damage. Methods: We conducted a prospective study within the INSPIRE registry including patients with newly diagnosed SLE (median disease duration 232 days [114–484]) with serum at baseline, 6 and 24 months. Anti-cardiolipin (aCL) and anti-β2-glycoprotein I (anti-β2GPI) IgG/IgM were measured by ELISA, and lupus anticoagulant when feasible. aPL positivity was analysed using manufacturer cut-offs and moderate–high titres (>40 U). Patients were classified as persistently negative, positive, fluctuating or negativized. High- and low-risk aPL profiles were defined per EULAR recommendations. Associations with thrombosis, SLEDAI-2K, Physician Global Assessment (PGA) and SLICC/ACR Damage Index (SDI) were assessed. Results: Among 270 patients, 77.1% were aPL positive at least once, predominantly low-titre. Moderate–high titre aPLs were less frequent and stable. Most patients with baseline negativity or low-titre/single positivity reverted to negative, whereas dual or triple positivity was associated with persistence. A subgroup (3.1%) progressed from negative/low-titre to high-risk profiles. aPL negativization occurred in 12.5% and was inversely associated with baseline aPL burden. Over 2 years, 19 (7%) developed thrombosis, with higher risk in high-risk and persistently positive groups; no thrombotic events occurred in persistently aPL-negative patients. aPL titres did not correlate with SLEDAI-2K or PGA, while aCL IgG and anti-β2GPI IgG correlated weakly with anti-dsDNA. SDI remained low across groups. Conclusion: In early SLE, aPLs are largely low-titre and fluctuating, with some patients evolving to higher-risk states, supporting serial aPL testing.
- 1 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (8)
Antiphospholipid antibody trajectories and clinical correlates in an inception cohort of systemic lupus erythematosus
Objective: To evaluate longitudinal antiphospholipid antibody (aPL) patterns in newly diagnosed systemic lupus erythematosus (SLE) and their association with vascular events, disease activity and organ damage. Methods: We conducted a prospective study within the INSPIRE registry including patients with newly diagnosed SLE (median disease duration 232 days [114–484]) with serum at baseline, 6 and 24 months. Anti-cardiolipin (aCL) and anti-β2-glycoprotein I (anti-β2GPI) IgG/IgM were measured by ELISA, and lupus anticoagulant when feasible. aPL positivity was analysed using manufacturer cut-offs and moderate–high titres (>40 U). Patients were classified as persistently negative, positive, fluctuating or negativized. High- and low-risk aPL profiles were defined per EULAR recommendations. Associations with thrombosis, SLEDAI-2K, Physician Global Assessment (PGA) and SLICC/ACR Damage Index (SDI) were assessed. Results: Among 270 patients, 77.1% were aPL positive at least once, predominantly low-titre. Moderate–high titre aPLs were less frequent and stable. Most patients with baseline negativity or low-titre/single positivity reverted to negative, whereas dual or triple positivity was associated with persistence. A subgroup (3.1%) progressed from negative/low-titre to high-risk profiles. aPL negativization occurred in 12.5% and was inversely associated with baseline aPL burden. Over 2 years, 19 (7%) developed thrombosis, with higher risk in high-risk and persistently positive groups; no thrombotic events occurred in persistently aPL-negative patients. aPL titres did not correlate with SLEDAI-2K or PGA, while aCL IgG and anti-β2GPI IgG correlated weakly with anti-dsDNA. SDI remained low across groups. Conclusion: In early SLE, aPLs are largely low-titre and fluctuating, with some patients evolving to higher-risk states, supporting serial aPL testing.
- 9 June 2026
- Published by Springer Nature in Aerobiologia
- Vol. 42 (1)
Characterization of a 40-kDa pectin methylesterase as a candidate pollen allergen from Parthenium hysterophorus
- 9 June 2026
- Published by Springer Nature in Aerobiologia
- Vol. 42 (1)
Characterization of a 40-kDa pectin methylesterase as a candidate pollen allergen from Parthenium hysterophorus
- 1 November 2025
- Published by Edra SpA in European Annals of Allergy and Clinical Immunology
- Vol. 57 (06) , 260
Functional characterization of complete and immunodominant epitopes of a novel pollen allergen from Parthenium hysterophorus
- 1 November 2025
- Published by Edra SpA in European Annals of Allergy and Clinical Immunology
- Vol. 57 (06) , 260
Functional characterization of complete and immunodominant epitopes of a novel pollen allergen from Parthenium hysterophorus
- 16 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70328
Pregnancy Outcomes in Women With Systemic Lupus Erythematosus ( SLE ): A Matched‐Observational Study From India
Aims: To assess the strength of the association of systemic lupus erythematosus (SLE) with feto‐maternal outcomes compared to those without SLE (healthy controls) beyond 20 weeks of gestation, and to determine the factors associated with a flare during pregnancy and postpartum among those with SLE. Methods: This matched‐observational study was conducted between 2011 and 2020 in a tertiary referral center in southeastern India, comparing feto‐maternal outcomes such as preterm birth, hypertensive disorders of pregnancy (HDP), small for gestational age (SGA), among pregnancies that crossed 20 weeks, with and without SLE (ratio of 1:1). Rates of lupus flare among cases were studied. Conditional logistic regression assessed the association between SLE and fetal‐maternal outcomes matched for age, whereas factors associated with lupus flare were assessed by multivariate logistic regression, expressed as adjusted odds ratios (OR) with a 95% confidence interval (95% CI). Results: During the study period, there were 144 cases of SLE, and 27 (18.8%) were diagnosed for the first time during pregnancy. Those with SLE had higher odds for HDP (OR: 5.10, 95% CI: 2.39–10.88), SGA (OR: 2.21, 95% CI: 1.24–3.91), preterm birth (< 37 weeks) (OR: 2.61, 95% CI: 1.36–5.02), and perinatal loss (OR: 13.92, 95% CI: 1.79–108.45), than those without SLE ( n = 144). The most common neonatal lupus presentation was complete heart block. Among those with SLE, HDP (OR: 9.99, 95% CI: 2.42–41.26) and lupus nephritis (OR: 4.62, 95% CI: 1.21–17.63) increased the risk of perinatal loss. Flares occurred in 27 (18.8%) cases, with six having multiple flares, and hydroxychloroquine was associated with its reduction (OR: 0.15, 95% CI: 0.03–0.71). Conclusion: Pregnant women with SLE had a higher risk of adverse feto‐maternal outcomes than those without SLE, beyond 20 weeks of gestation. Lupus nephritis and HDP increase the risk of perinatal loss, whereas hydroxychloroquine usage reduces lupus flare.
- 16 June 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (6) , e70328
Pregnancy Outcomes in Women With Systemic Lupus Erythematosus ( SLE ): A Matched‐Observational Study From India
Aims: To assess the strength of the association of systemic lupus erythematosus (SLE) with feto‐maternal outcomes compared to those without SLE (healthy controls) beyond 20 weeks of gestation, and to determine the factors associated with a flare during pregnancy and postpartum among those with SLE. Methods: This matched‐observational study was conducted between 2011 and 2020 in a tertiary referral center in southeastern India, comparing feto‐maternal outcomes such as preterm birth, hypertensive disorders of pregnancy (HDP), small for gestational age (SGA), among pregnancies that crossed 20 weeks, with and without SLE (ratio of 1:1). Rates of lupus flare among cases were studied. Conditional logistic regression assessed the association between SLE and fetal‐maternal outcomes matched for age, whereas factors associated with lupus flare were assessed by multivariate logistic regression, expressed as adjusted odds ratios (OR) with a 95% confidence interval (95% CI). Results: During the study period, there were 144 cases of SLE, and 27 (18.8%) were diagnosed for the first time during pregnancy. Those with SLE had higher odds for HDP (OR: 5.10, 95% CI: 2.39–10.88), SGA (OR: 2.21, 95% CI: 1.24–3.91), preterm birth (< 37 weeks) (OR: 2.61, 95% CI: 1.36–5.02), and perinatal loss (OR: 13.92, 95% CI: 1.79–108.45), than those without SLE ( n = 144). The most common neonatal lupus presentation was complete heart block. Among those with SLE, HDP (OR: 9.99, 95% CI: 2.42–41.26) and lupus nephritis (OR: 4.62, 95% CI: 1.21–17.63) increased the risk of perinatal loss. Flares occurred in 27 (18.8%) cases, with six having multiple flares, and hydroxychloroquine was associated with its reduction (OR: 0.15, 95% CI: 0.03–0.71). Conclusion: Pregnant women with SLE had a higher risk of adverse feto‐maternal outcomes than those without SLE, beyond 20 weeks of gestation. Lupus nephritis and HDP increase the risk of perinatal loss, whereas hydroxychloroquine usage reduces lupus flare.
- 24 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4283-4291
Immunosuppressant withdrawal versus glucocorticoid withdrawal in SLE: 2-year outcomes of a noninferiority randomized controlled trial
Objectives: This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission. Methods: In this open-label, single-centre, randomized (1:1) controlled trial, we compared flare occurrence in stable SLE patients undergoing GC or IS tapering. Patients aged >18, on stable GC (prednisolone ≤7.5 mg/day) and maintenance non-biological IS for ≥3 years, in clinical remission for ≥1 year, were enrolled and assigned to taper GC or IS over 3 months. The primary endpoint was the proportion of patients experiencing a flare, defined by the SELENA-SLEDAI Flare Index (SFI) at 52 weeks. Patients in remission beyond 52 weeks were followed up to the maximum available follow-up duration beyond 104 weeks. Results: Between May and December 2021, 121 patients were randomized, and 117 (GC withdrawal, n = 58; IS withdrawal, n = 59) were included in the primary analysis. Flare occurred in 31% of the GC withdrawal group and 20.3% in the IS withdrawal group (risk difference, –10.6% [95% CI, −26.5 to 5.1]; P = 0.18), demonstrating the noninferiority of IS withdrawal. At maximum follow-up, 44.8% in the GC withdrawal group and 32.2% in the IS withdrawal group experienced a flare (risk difference, −12.6% [95% CI, −30.1 to 4.9]; P = 0.11), confirming the noninferiority of IS withdrawal at 2 years. Damage accrual was similar between the two groups at both endpoints. Conclusion: IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. Personalized tapering strategies based on baseline damage and steroid exposure may optimize outcomes. Trial registration: The trial was registered with https://ctri.nic.in/, CTRI/2020/07/026712.
- 24 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (7) , 4283-4291
Immunosuppressant withdrawal versus glucocorticoid withdrawal in SLE: 2-year outcomes of a noninferiority randomized controlled trial
Objectives: This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission. Methods: In this open-label, single-centre, randomized (1:1) controlled trial, we compared flare occurrence in stable SLE patients undergoing GC or IS tapering. Patients aged >18, on stable GC (prednisolone ≤7.5 mg/day) and maintenance non-biological IS for ≥3 years, in clinical remission for ≥1 year, were enrolled and assigned to taper GC or IS over 3 months. The primary endpoint was the proportion of patients experiencing a flare, defined by the SELENA-SLEDAI Flare Index (SFI) at 52 weeks. Patients in remission beyond 52 weeks were followed up to the maximum available follow-up duration beyond 104 weeks. Results: Between May and December 2021, 121 patients were randomized, and 117 (GC withdrawal, n = 58; IS withdrawal, n = 59) were included in the primary analysis. Flare occurred in 31% of the GC withdrawal group and 20.3% in the IS withdrawal group (risk difference, –10.6% [95% CI, −26.5 to 5.1]; P = 0.18), demonstrating the noninferiority of IS withdrawal. At maximum follow-up, 44.8% in the GC withdrawal group and 32.2% in the IS withdrawal group experienced a flare (risk difference, −12.6% [95% CI, −30.1 to 4.9]; P = 0.11), confirming the noninferiority of IS withdrawal at 2 years. Damage accrual was similar between the two groups at both endpoints. Conclusion: IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. Personalized tapering strategies based on baseline damage and steroid exposure may optimize outcomes. Trial registration: The trial was registered with https://ctri.nic.in/, CTRI/2020/07/026712.
- Open Access
- 29 August 2024
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 19 (4) , 262-272
Role of Galectin-9, CXCL-10, APRIL, TNFRII and BAFF as Biomarkers in Idiopathic Inflammatory Myopathy: A Longitudinal Cohort Study
Objective: The study aimed to evaluate serum biomarkers (Galectin-9, TNFRII, APRIL, CXCL10, and BAFF) for their utility in identifying disease activity in idiopathic inflammatory myopathies (IIM) Methods: We enrolled adult patients who satisfied the 2017 EULAR/ACR criteria for IIM and categorised them into active (n = 16) and inactive (n = 24) subgroups. Inactive disease was defined as the absence of global and extramuscular activity, stable manual muscle testing 8 (MMT-8), and normal muscle enzymes over at least 6 months. We measured serum biomarkers by enzyme-linked immunosorbent assay (ELISA) at baseline, 3 and 6 months. We employed Spearman’s correlation, ROC curves, and multiple linear regression for evaluation. Results: We included 40 patients (mean age 38 ± 10 years; median disease duration 27.5 months). The majority had dermatomyositis (DM) (62.5%), followed by anti-synthetase syndrome (ASSD) (27.5%) and polymyositis (10%). Galectin-9, APRIL, and TNFRII levels were significantly higher in active disease ( P < .05). Galectin-9 demonstrated a modest correlation with MMT-8 changes (r = 0.534). A combination of Galectin-9, TNFRII, APRIL and creatine kinase (CK) levels showed the highest ROC AUC (0.953) to detect active disease. During the study, four patients initially categorised as ‘inactive’ patients exhibited improvement of 10% in MMT-8 over 6 months. To enhance sensitivity for detecting these clinically active diseases, we assessed Galectin-9 at lower cut-offs. Levels of 1146 pg/mL and 1109 pg/mL improved sensitivity to identify active disease to 81% and 87%, respectively, without compromising specificity. Conclusion: Serum biomarkers, Galectin-9, TNFRII, and APRIL, may help in differentiating between active and inactive disease in adult IIM. Notably, persistently elevated Galectin-9 levels, even in clinically quiescent disease, may signify ongoing activity.
- 29 August 2024
- Published by SAGE Publications in Indian Journal of Rheumatology
- Vol. 19 (4) , 262-272
Open AccessRole of Galectin-9, CXCL-10, APRIL, TNFRII and BAFF as Biomarkers in Idiopathic Inflammatory Myopathy: A Longitudinal Cohort Study
Objective: The study aimed to evaluate serum biomarkers (Galectin-9, TNFRII, APRIL, CXCL10, and BAFF) for their utility in identifying disease activity in idiopathic inflammatory myopathies (IIM) Methods: We enrolled adult patients who satisfied the 2017 EULAR/ACR criteria for IIM and categorised them into active (n = 16) and inactive (n = 24) subgroups. Inactive disease was defined as the absence of global and extramuscular activity, stable manual muscle testing 8 (MMT-8), and normal muscle enzymes over at least 6 months. We measured serum biomarkers by enzyme-linked immunosorbent assay (ELISA) at baseline, 3 and 6 months. We employed Spearman’s correlation, ROC curves, and multiple linear regression for evaluation. Results: We included 40 patients (mean age 38 ± 10 years; median disease duration 27.5 months). The majority had dermatomyositis (DM) (62.5%), followed by anti-synthetase syndrome (ASSD) (27.5%) and polymyositis (10%). Galectin-9, APRIL, and TNFRII levels were significantly higher in active disease ( P < .05). Galectin-9 demonstrated a modest correlation with MMT-8 changes (r = 0.534). A combination of Galectin-9, TNFRII, APRIL and creatine kinase (CK) levels showed the highest ROC AUC (0.953) to detect active disease. During the study, four patients initially categorised as ‘inactive’ patients exhibited improvement of 10% in MMT-8 over 6 months. To enhance sensitivity for detecting these clinically active diseases, we assessed Galectin-9 at lower cut-offs. Levels of 1146 pg/mL and 1109 pg/mL improved sensitivity to identify active disease to 81% and 87%, respectively, without compromising specificity. Conclusion: Serum biomarkers, Galectin-9, TNFRII, and APRIL, may help in differentiating between active and inactive disease in adult IIM. Notably, persistently elevated Galectin-9 levels, even in clinically quiescent disease, may signify ongoing activity.
- 24 April 2024
- Published by Elsevier in Immunology Letters
- Vol. 267, 106859
Rheumatoid arthritis autologous synovial fluid affects the plasticity and function of peripheral and induced T regulatory cells in vitro
- 24 April 2024
- Published by Elsevier in Immunology Letters
- Vol. 267, 106859
Rheumatoid arthritis autologous synovial fluid affects the plasticity and function of peripheral and induced T regulatory cells in vitro
- 27 December 2023
- Published by Springer Nature in Immunologic Research
- Vol. 72 (3) , 396-408
Conventional Tregs in treatment-naïve rheumatoid arthritis are deficient in suppressive function with an increase in percentage of CXCR3 and CCR6 expressing Tregs
In rheumatoid arthritis (RA), immune homeostasis is maintained by T regulatory cells (Tregs) that in an inflammatory milieu can change towards T-helper-like phenotypes (Th-like Tregs). Our aim was to examine the phenotypic and functional characteristics of CD4+CD25+CD127lo/− Tregs, Th-like Tregs and T effector (Teff) cells in the peripheral blood (PB) and synovial fluid (SF) of treatment-naïve early RA, as compared to osteoarthritis (OA) and healthy control (HC) peripheral blood. Frequencies of Tregs, CXCR3, CCR6 expressing Tregs (Th-like Tregs), and Teff cells were analyzed using flow cytometry in RA (n = 80), OA (n = 20), and HC (n = 40). Cytokine concentrations of the respective T cell subsets in plasma and SF were measured using flow cytometric bead array. Tregs sorted from RA and HC PB using magnetic beads were analyzed for functional capacities by CFSE proliferation assay and FOXP3 gene expression using real-time PCR. We observed that the frequencies of Th17 cells in PB and SF were significantly higher in RA when compared to HC, whereas Tregs were lower in PB and high in SF compared to HC and OA respectively. Th1- and Th17-related pro-inflammatory cytokines IL12p70, INF-γ, TNF-α, and IL-6, and IL-17A were significantly higher in the plasma and SF of RA. Tregs expressing CXCR3 (Th1-like Tregs) and CCR6 (Th17-like Treg) were significantly higher in PB and SF of RA compared to controls and was positively associated with seropositivity and disease activity. Treg cells isolated from peripheral blood of RA showed decreased function and reduced FOXP3 gene expression compared to HC. In our study, we have demonstrated higher frequencies of Th1 and Th17 cells and increased circulatory and SF pro-inflammatory cytokines (IL12P70, INF-γ, IL-6, IL-17A, and TNF-α) in RA. This inflammatory milieu might alter total Tregs frequencies and influence conversion of Tregs into Th-like Tregs.
- 27 December 2023
- Published by Springer Nature in Immunologic Research
- Vol. 72 (3) , 396-408
Conventional Tregs in treatment-naïve rheumatoid arthritis are deficient in suppressive function with an increase in percentage of CXCR3 and CCR6 expressing Tregs
In rheumatoid arthritis (RA), immune homeostasis is maintained by T regulatory cells (Tregs) that in an inflammatory milieu can change towards T-helper-like phenotypes (Th-like Tregs). Our aim was to examine the phenotypic and functional characteristics of CD4+CD25+CD127lo/− Tregs, Th-like Tregs and T effector (Teff) cells in the peripheral blood (PB) and synovial fluid (SF) of treatment-naïve early RA, as compared to osteoarthritis (OA) and healthy control (HC) peripheral blood. Frequencies of Tregs, CXCR3, CCR6 expressing Tregs (Th-like Tregs), and Teff cells were analyzed using flow cytometry in RA (n = 80), OA (n = 20), and HC (n = 40). Cytokine concentrations of the respective T cell subsets in plasma and SF were measured using flow cytometric bead array. Tregs sorted from RA and HC PB using magnetic beads were analyzed for functional capacities by CFSE proliferation assay and FOXP3 gene expression using real-time PCR. We observed that the frequencies of Th17 cells in PB and SF were significantly higher in RA when compared to HC, whereas Tregs were lower in PB and high in SF compared to HC and OA respectively. Th1- and Th17-related pro-inflammatory cytokines IL12p70, INF-γ, TNF-α, and IL-6, and IL-17A were significantly higher in the plasma and SF of RA. Tregs expressing CXCR3 (Th1-like Tregs) and CCR6 (Th17-like Treg) were significantly higher in PB and SF of RA compared to controls and was positively associated with seropositivity and disease activity. Treg cells isolated from peripheral blood of RA showed decreased function and reduced FOXP3 gene expression compared to HC. In our study, we have demonstrated higher frequencies of Th1 and Th17 cells and increased circulatory and SF pro-inflammatory cytokines (IL12P70, INF-γ, IL-6, IL-17A, and TNF-α) in RA. This inflammatory milieu might alter total Tregs frequencies and influence conversion of Tregs into Th-like Tregs.
- 21 November 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (12) , 2885-2889
Kidney histopathology in predicting flares following drug withdrawal in proliferative lupus nephritis in clinical remission
Residual renal histopathological activity at clinical remission in Proliferative Lupus Nephritis (PLN) can predict renal flare upon immunosuppression withdrawal. Data on the role of histological renal remission in predicting extra-renal flares is lacking. We assessed renal histopathology prior to drug withdrawal and the occurrence of renal and extra-renal flares over 52 weeks after drug withdrawal in PLN patients in long-term clinical remission. This is a subgroup analysis of a non-inferiority, open-label randomized (1:1) controlled trial. Patients with biopsy-proven Class III/IV LN in the past (biopsy 1), on immunosuppressants (IS) ≥ 3 years, in clinical remission for ≥ 1 year, on stable prednisolone dose (≤ 7.5 mg/day) plus a maintenance IS and hydroxychloroquine (HCQ) were subjected to a repeat renal biopsy (biopsy 2). Individuals with biopsy 2 having activity index (AI) < 4/24 were randomised to either prednisolone or IS withdrawal. Primary end-point was the proportion experiencing a flare [SELENA-SLEDAI flare index (SFI)] at week 52. Twenty-eight eligible patients underwent biopsy 2 and randomized to prednisolone (n = 15) and IS (n = 13) withdrawal. At biopsy 1, 12 (43%) had class III, 15 (53.5%) had class IV, and 1 (3.5%) had class III + V. At biopsy 2, PLN persisted in 4 (14.2%) while 18 (64.2%) were in histological remission (AI = 0) with 6 (21.4%) in class II. Following drug withdrawal, 9/28 (32%) had flares especially musculoskeletal (55.5%), mucocutaneous (44.4%), and renal (33.3%). Among the four persistent PLN patients, one of the two (50%) with AI = 1 had extra-renal flare while both the two with AI = 2 (100%) had renal and extra-renal flares. In those with histological remission (biopsy 2), 6/18 (66.6%) experienced extra-renal flare of whom one also had renal flare. Upon drug withdrawal, renal histopathology findings with any activity index can predict renal flare while histological remission is not enough to predict extra-renal flare, thus making it an unsuitable marker for deep SLE remission.
- 21 November 2023
- Published by Springer Nature in Rheumatology International
- Vol. 44 (12) , 2885-2889
Kidney histopathology in predicting flares following drug withdrawal in proliferative lupus nephritis in clinical remission
Residual renal histopathological activity at clinical remission in Proliferative Lupus Nephritis (PLN) can predict renal flare upon immunosuppression withdrawal. Data on the role of histological renal remission in predicting extra-renal flares is lacking. We assessed renal histopathology prior to drug withdrawal and the occurrence of renal and extra-renal flares over 52 weeks after drug withdrawal in PLN patients in long-term clinical remission. This is a subgroup analysis of a non-inferiority, open-label randomized (1:1) controlled trial. Patients with biopsy-proven Class III/IV LN in the past (biopsy 1), on immunosuppressants (IS) ≥ 3 years, in clinical remission for ≥ 1 year, on stable prednisolone dose (≤ 7.5 mg/day) plus a maintenance IS and hydroxychloroquine (HCQ) were subjected to a repeat renal biopsy (biopsy 2). Individuals with biopsy 2 having activity index (AI) < 4/24 were randomised to either prednisolone or IS withdrawal. Primary end-point was the proportion experiencing a flare [SELENA-SLEDAI flare index (SFI)] at week 52. Twenty-eight eligible patients underwent biopsy 2 and randomized to prednisolone (n = 15) and IS (n = 13) withdrawal. At biopsy 1, 12 (43%) had class III, 15 (53.5%) had class IV, and 1 (3.5%) had class III + V. At biopsy 2, PLN persisted in 4 (14.2%) while 18 (64.2%) were in histological remission (AI = 0) with 6 (21.4%) in class II. Following drug withdrawal, 9/28 (32%) had flares especially musculoskeletal (55.5%), mucocutaneous (44.4%), and renal (33.3%). Among the four persistent PLN patients, one of the two (50%) with AI = 1 had extra-renal flare while both the two with AI = 2 (100%) had renal and extra-renal flares. In those with histological remission (biopsy 2), 6/18 (66.6%) experienced extra-renal flare of whom one also had renal flare. Upon drug withdrawal, renal histopathology findings with any activity index can predict renal flare while histological remission is not enough to predict extra-renal flare, thus making it an unsuitable marker for deep SLE remission.